Celiac Plexus Neurolysis for Pancreatic Cancer-associated Pain

Share this content:
Pain management continues to be a challenge for patients with pancreatic cancer, though CPN may provide significant pain relief and an opportunity to reduce the amount of required narcotics.
Pain management continues to be a challenge for patients with pancreatic cancer, though CPN may provide significant pain relief and an opportunity to reduce the amount of required narcotics.

One of the most challenging aspects of pancreatic cancer treatment is pain management. Nearly 80% of patients will have abdominal pain at time of diagnosis, and while the pain is typically epigastric, it may also occur in the upper abdomen and back.1 These patients also frequently experience additional gastrointestinal (GI) symptoms including nausea, vomiting, and weight loss.

Narcotics and non-narcotics are used to treat pancreatic cancer–associated pain, though non-narcotics, such as nonsteroidal anti-inflammatory drugs (NSAIDs) and acetaminophen, are frequently ineffective or may be contraindicated. Narcotics provide some pain relief but are associated with numerous side effects, such as nausea and constipation, which can compound the already-debilitating GI symptoms.

The celiac plexus, which is located in a branch of the abdominal aorta, is a nerve network linked with pancreatic cancer–associated pain. Procedures that target this network to modulate pain include celiac plexus block (CPB), which uses steroids such as triamcinolone, and celiac plexus neurolysis (CPN), which uses alcohol and bupivacaine.2,3

While CPB is a temporary treatment more often used for patients with chronic pancreatitis, CPN is a permanent treatment based on the use of alcohol as a neurolytic agent, and is more frequently used for patients with pancreatic cancer.

Both procedures can be performed endoscopically (endoscopic ultrasound [EUS]) or non-endoscopically (surgery, percutaneous), though the endoscopic route is performed more frequently. For CPB, triamcinolone is injected; CPN uses bupivacaine and alcohol. Studies evaluating CPN for pancreatic cancer-associated pain report pain relief among up to 80% of patients.4

Most adverse events (AEs) associated with these procedures are secondary to manipulation of the celiac plexus and the resulting alteration in the neurologic innervation. One study found a serious complication rate of less than 2%; observed AEs included hypotension, severe abdominal pain, and intra-abdominal abscess.5 Patients should therefore be closely monitored for hypotension both during and immediately after the procedure for hypotension. Hypotension may be seen beyond the immediate post-procedural monitoring period in these patients, but this is rare.

Patients can also experience post-procedural diarrhea, which in about 1% of cases is permanent. There are also some reports of a slightly increased infection risk among patients undergoing CPB who are on acid-suppressing medications such as proton pump inhibitors (PPIs) or histamine receptor blockers (H2RBs).6 As PPIs and H2RBs reduce the acidity of the GI tract, bacterial translocation during endoscopic manipulation of the celiac plexus may become more common. This AE is not as much of a concern in patients undergoing CPN, however, as the alcohol functions as a bactericidal agent.

Pain management continues to be a challenge for patients with pancreatic cancer, though CPN may provide significant pain relief and an opportunity to reduce the amount of required narcotics.

References

  1. Porta M, Fabregat X, Malats N, et al. Exocrine pancreatic cancer: symptoms at presentation and their relation to tumour site and stage. Clin Transl Oncol. 2005;7(5):189-97.
  2. Puli SR, Reddy JB, Bechtold ML, Antillon MR, Brugge WR. EUS-guided celiac plexus neurolysis for pain due to chronic pancreatitis or pancreatic cancer related pain: a meta-analysis and literature review. Dig Dis Sci. 2009;54(11):2330-7.
  3. Kaufman M, Singh G, Das S, et al. Efficacy of endoscopic ultrasound-guided celiac plexus block and celiac plexus neurolysis for managing abdominal pain associated with chronic pancreatitis and pancreatic cancer. J Clin Gastroenterol. 2010;44(2):127.
  4. Gunaratnam NT, Sarma AV, Norton ID, Wiersema MJ. A prospective study of EUS-guided celiac plexus neurolysis for pancreatic cancer pain. Gastrointest Endosc. 2001;54(3):316-24.
  5. O'Toole TM, Schmulewitz N. Complication rates of EUS-guided celiac plexus blockade and neurolysis: results of a large case series. Endoscopy. 2009;41(7):593-7.
  6. Gress F, Schmitt C, Sherman S, Ciaccia D, Ikenberry S, Lehman G. Endoscopic ultrasound-guided celiac plexus block for managing abdominal pain associated with chronic pancreatitis: a prospective single center experience. Am J Gastroenterol. 2001;96(2):409-16.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters